3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Promyelocytic, Acute
5
Thrombocytopenia
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Leukemia
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Primary Myelofibrosis
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Oligometastatic Disease
1
Oligodendroglioma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
HER2 Negative Breast Cancer
1
Glioma
1
Interventions
Cyclophosphamide
43
venetoclax
30
Cytarabine
25
fludarabine
22
fludarabine phosphate
17
Azacitidine
16
Mycophenolic Acid
13
Whole-Body Irradiation
12
Dexamethasone
12
Rituximab
11
Busulfan
11
ruxolitinib
10
Vincristine
10
Methotrexate
10
Etoposide
10
Tacrolimus
9
Mercaptopurine
9
Daunorubicin
9
Prednisone
8
Filgrastim
8
Dasatinib
8
ibrutinib
7
Peripheral Blood Stem Cell Transplantation
7
Melphalan
7
Granulocyte Colony-Stimulating Factor
7
Doxorubicin
7
Decitabine
7
pegaspargase
6
blinatumomab
6
Mesna
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Leukemia
×
Tretinoin
×
1 year
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled
NCT07296445
2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3
Not yet recruiting
120 enrolled